Natco Pharma Share Price | Natco Pharma Stock Screener
NATCOPHARM
Pharmaceuticals
Share Price NSE
₹1175.80
▼
-10.20 (-0.86%)
Share Price BSE
₹1175.60
▼
-11.40 (-0.96%)
As of May 27, 2026, the Natco Pharma share price (NSE: NATCOPHARM) is ₹1,175.80 on NSE and ₹1,175.60 on BSE, down 0.86% from the previous close, with shares trading between ₹1,170.30 and ₹1,202.00, and a 52-week range of ₹792.95–₹1,206.00.
Check Natco Pharma yearly highs lows for the annual price range and momentum.
Use the Natco Pharma stock screener below to analyse P/E ratio, market cap, quarterly results, and more. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Natco Pharma Market Cap
₹20,950.50 Cr.
NATCOPHARM P/E Ratio (TTM)
13.47
Natco Pharma P/B Ratio
2.42
EPS (TTM)
₹105.26
Dividend Yield
0.51%
Debt to Equity
0.05
NATCOPHARM 52 Week High
₹1206.00
Natco Pharma 52 Week Low
₹792.95
Operating Margin
25.00%
Profit Margin
21.42%
NATCOPHARM Revenue (TTM)
₹705.00
EBITDA
₹217.00
Net Income
₹151.00
Total Assets
₹8,631.00
Total Equity
₹7,612.00
Natco Pharma Share Price Chart
Screen Natco Pharma share price with an interactive chart. Analyse NATCOPHARM price trends and volatility across different timeframes.
Natco Pharma Company Profile - Fundamental Screener
Screen Natco Pharma company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics
for NATCOPHARM shares.
Natco Pharma Limited is a vertically integrated pharmaceutical company specializing in the development, manufacturing, and marketing of Finished Dosage Formulations and Active Pharmaceutical Ingredients. The company focuses on niche therapeutic areas and complex products, selling in over 40 countries. Natco operates in the Pharmaceuticals and Agro chemicals segments, with nine...more
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
Chairperson/CEO
V C Nannapaneni
ISIN
INE987B01026
Website
https://www.natcopharma.co.in
Natco Pharma Balance Sheet Screener
Screen NATCOPHARM balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation
metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 8,631 | 6,906 | 5,657 | 5,109 | 4,792 | 4,588 | 4,303 | 3,715 | 2,318 | 1,822 |
| Current Assets | 5,270 | 4,024 | 3,000 | 2,497 | 2,337 | 2,326 | 2,347 | 2,131 | 1,087 | 837 |
| Fixed Assets | 2,698 | 2,491 | 2,427 | 2,312 | 2,023 | 1,584 | 1,227 | 1,019 | 833 | 710 |
| Liabilities | ||||||||||
| Total Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Current Liabilities | 75 | 80 | 101 | 135 | 143 | 118 | 83 | 47 | 38 | 28 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 7,612 | 5,853 | 4,874 | 4,264 | 4,123 | 3,785 | 3,491 | 3,076 | 1,653 | 1,301 |
| Share Capital | 36 | 36 | 37 | 37 | 37 | 36 | 37 | 37 | 35 | 35 |
| Reserves & Surplus | 7,571 | 5,817 | 4,837 | 4,227 | 4,085 | 3,737 | 3,453 | 3,035 | 1,614 | 1,261 |
Natco Pharma Income Statement Screener - Profit & Revenue Analysis
Screen Natco Pharma income statement and profit fundamentals.
Analyze NATCOPHARM quarterly results,
revenue growth, EBITDA, net profit margins, and EPS using TickJournal's fundamental screener for Natco Pharma share price evaluation.
| Item | 2025-Dec | 2025-Sept | 2025-Jun | 2025-Mar | 2024-Dec | 2024-Sept | 2024-Jun | 2024-Mar | 2023-Dec | 2023-Sept | 2023-Jun | 2023-Mar | 2022-Dec | 2022-Sept | 2022-Jun |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 705 | 1,463 | 1,391 | 1,287 | 651 | 1,435 | 1,411 | 1,110 | 796 | 1,061 | 1,160 | 927 | 513 | 453 | 919 |
| Expenses | 489 | 784 | 758 | 673 | 436 | 567 | 558 | 571 | 491 | 573 | 613 | 559 | 387 | 337 | 489 |
| EBITDA | 217 | 679 | 633 | 614 | 215 | 868 | 853 | 539 | 305 | 487 | 548 | 368 | 127 | 116 | 430 |
| Operating Profit % | 25.00% | 42.00% | 43.00% | 45.00% | 8.00% | 59.00% | 59.00% | 47.00% | 35.00% | 44.00% | 46.00% | 38.00% | 22.00% | 22.00% | 45.00% |
| Depreciation | 46 | 52 | 58 | 98 | 47 | 46 | 44 | 56 | 44 | 44 | 44 | 41 | 42 | 42 | 40 |
| Interest | 10 | 13 | 3 | 10 | 4 | 4 | 5 | 6 | 5 | 4 | 4 | 3 | 4 | 4 | 4 |
| Profit Before Tax | 161 | 614 | 572 | 506 | 164 | 818 | 804 | 478 | 256 | 440 | 500 | 324 | 81 | 70 | 386 |
| Tax | 10 | 96 | 92 | 100 | 31 | 142 | 135 | 91 | 44 | 71 | 80 | 49 | 19 | 14 | 65 |
| Net Profit | 151 | 518 | 480 | 406 | 132 | 677 | 669 | 386 | 213 | 369 | 420 | 276 | 62 | 57 | 320 |
| EPS | 8.46 | 28.94 | 26.84 | 22.70 | 7.43 | 37.81 | 37.32 | 21.56 | 11.88 | 20.60 | 23.26 | 15.11 | 3.41 | 3.11 | 22.55 |
Natco Pharma Cash Flow Screener - Liquidity Fundamentals
Screen NATCOPHARM cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price
strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 1,697 | 1,212 | 849 | 47 | 299 | 417 | 669 | 464 | 346 | 112 |
| Investing Activities | -1,437 | -1,026 | -465 | 4 | -107 | -175 | -611 | -1,116 | -299 | -176 |
| Financing Activities | -211 | -247 | -363 | 35 | -186 | -251 | -51 | 651 | -48 | 154 |
| Net Cash Flow | 50 | -62 | 21 | 85 | 6 | -9 | 7 | -2 | -1 | 90 |
Natco Pharma Shareholding Pattern Screener
See Natco Pharma shareholding pattern with promoter, FII, and DII holdings.
Check Natco Pharma promoter holding and ownership changes for NATCOPHARM on TickJournal.
| Item | 2026-Mar | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 49.42% | 49.56% | 49.56% | 49.48% | 49.48% | 49.71% | 49.71% | 49.62% |
| FII Holding | 17.37% | 17.49% | 15.51% | 14.09% | 15.16% | 16.14% | 17.45% | 17.51% |
| DII Holding | 5.46% | 5.65% | 5.82% | 5.87% | 5.39% | 9.70% | 7.87% | 6.75% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.34% | 23.68% | 25.22% | 25.84% | 25.38% | 20.60% | 21.59% | 22.60% |
| Other Holding | 4.41% | 3.61% | 3.89% | 4.72% | 4.58% | 3.85% | 3.39% | 3.52% |
| Shareholder Count | 410,970 | 405,222 | 429,434 | 419,699 | 424,167 | 228,467 | 251,485 | 302,944 |
Natco Pharma Share Dividend Screener - Share Yield Analysis
Check Natco Pharma dividend history with payout and yield data.
View Natco Pharma dividend details including ex-dates and amounts for NATCOPHARM stock.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹6.00 | 0.62% |
| 2024-March | ₹9.50 | 1.19% |
| 2023-March | ₹5.50 | 0.58% |
| 2022-March | ₹4.50 | 0.81% |
| 2021-March | ₹5.25 | 0.69% |
| 2020-March | ₹6.75 | 0.82% |
| 2019-March | ₹6.25 | 1.24% |
| 2018-March | ₹8.25 | 1.44% |
| 2017-March | ₹6.75 | 0.90% |
Natco Pharma Stock Index Membership
See which indices include Natco Pharma stock.
Check NATCOPHARM index membership in NIFTY 50, SENSEX, and other indices on TickJournal.
BSE 1000
BSE INDEX BSE HC
BSE INDEX BSE500
BSE INDEX MSL400
BSE INDEX SML250
BSE INDEX SMLCAP
BSE INDEX SMLSEL
NIFTY 500
NIFTY MIDSMALLCAP400 MOMENTUM QUALITY 100
NIFTY MIDSML 400
NIFTY MIDSML HLTH
NIFTY MULTI MFG
NIFTY PHARMA
NIFTY SMALLCAP250 MOMENTUM QUALITY 100
NIFTY SMLCAP 100
NIFTY SMLCAP 250
NIFTY SMLCAP 50
NIFTY TOTAL MKT
NIFTY500 EQUAL WEIGHT
NIFTY500 LARGEMIDSMALL EQUAL CAP WEIGHTED
NIFTY500 MOMENTUM 50
NIFTY500 MULTICAP
NIFTY500 MULTICAP MOMENTUM QUALITY 50
NIFTY500 SHARIAH
Natco Pharma Market Events Screener - Corporate Actions
Get Natco Pharma corporate actions including splits, bonuses, and buybacks.
Check Natco Pharma stock events that may affect NATCOPHARM share price.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Annual General Meeting | NA | -3.48% | ||
| Annual General Meeting | NA | -0.11% | ||
| Annual General Meeting | NA | -1.94% | ||
| 2026-05-29 | 2026-05-29 | Quarterly Result Announcement | NA | -2.34% |
| 2026-02-18 | 2026-02-18 | Dividend | ₹ 1.50 /share | 3.98% |
| 2026-02-12 | 2026-02-12 | Quarterly Result Announcement | NA | 4.49% |
| 2025-11-20 | 2025-11-20 | Dividend | ₹ 1.50 /share | 0.48% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 3.21% |
| 2025-08-19 | 2025-08-19 | Dividend | ₹ 2.00 /share | -2.87% |
| 2025-08-12 | 2025-08-12 | Quarterly Result Announcement | NA | -2.84% |
| 2025-05-28 | 2025-05-28 | Quarterly Result Announcement | NA | 8.46% |
| 2025-02-18 | 2025-02-18 | Dividend | ₹ 1.50 /share | -29.89% |
| 2025-02-12 | 2025-02-12 | Quarterly Result Announcement | NA | 5.63% |
| 2024-11-27 | 2024-11-27 | Dividend | ₹ 1.50 /share | -2.91% |
| 2024-11-12 | 2024-11-12 | Quarterly Result Announcement | NA | 8.04% |
Natco Pharma Competitors Screener - Peer Comparison
Screen NATCOPHARM competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better
stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 442,581 | 40.42 | 58,220 | 6.38% | 11,565 | 54.75 |
| Divis Laboratories | 182,828 | 73.73 | 10,560 | 8.73% | 2,520 | 66.48 |
| Torrent Pharmaceuticals | 151,833 | 66.80 | 13,753 | 19.18% | 2,028 | 61.90 |
| Cipla | 113,025 | 29.26 | 27,712 | -2.46% | 3,783 | 61.92 |
| Dr Reddys Laboratories | 109,105 | 26.24 | 33,593 | -0.44% | 3,998 | 52.61 |
| Zydus Life Science | 104,543 | 20.40 | 26,720 | 13.65% | 5,242 | 69.40 |
| Lupin | 104,288 | 19.46 | 27,488 | 19.98% | 5,345 | 47.33 |
| Mankind Pharma | 102,351 | 52.84 | 14,278 | 12.03% | 1,750 | 62.34 |
| Aurobindo Pharma | 85,000 | 24.29 | 33,385 | 3.21% | 3,376 | 52.91 |
| Laurus Labs | 72,530 | 81.46 | 6,813 | 21.03% | 884 | 77.10 |
Natco Pharma Company Announcements - News Screener
Screen NATCOPHARM latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-05-25 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-05-22 | Board Meeting Intimation for Considering Audited Financial Results For The Financial Year Ended 31St March 2026 | - |
| 2026-05-19 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-05-18 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 | - |
| 2026-04-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2026-03-31 | Closure of Trading Window | - |
| 2026-03-25 | Shareholder Meeting / Postal Ballot-Outcome of Postal_Ballot | - |
| 2026-03-24 | Announcement under Regulation 30 (LODR)-Acquisition | - |
| 2026-03-24 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2026-03-24 | Board Meeting Outcome for Outcome Of Board Meeting Held On 24Th March 2026 | - |
| 2026-03-20 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-03-18 | Board Meeting Intimation for Approving The Scheme Of Arrangement (Demerger) | - |
| 2026-03-13 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-13 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2026-03-06 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | - |
| 2026-03-03 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | - |
| 2026-02-25 | Clarification On Volume Movement Of Shares | - |
| 2026-02-25 | Clarification sought from Natco Pharma Ltd | - |
| 2026-02-25 | Rumour verification - Regulation 30(11) | - |
| 2026-02-24 | Clarification sought from Natco Pharma Ltd | - |